Zerbaxa generic
Zerbaxa is an antibiotic drug owned by Cubist Pharms Llc. It contains Ceftolozane Sulfate and Tazobactam Sodium. It was first authorized for market use on 19th December 2014. The drug has a total of 14 patents with none expired yet.
When will Zerbaxa generic be available?
The generic version of Zerbaxa is expected to be available after 14th August 2035, following the expiration of the last patent. Drug patent challenges may be filed against Zerbaxa from 20th December 2023.
Zerbaxa uses
Zerbaxa is used for the treatment of various bacterial infections. These include but are not limited to hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated urinary tract infections, especially in patients with end-stage renal disease on hemodialysis, and complicated intra-abdominal infections.
Zerbaxa patent expiration
Zerbaxa has a total of 14 patents. The patents cover methods of treating intrapulmonary infections, Ceftolozane antibiotic compositions, Ceftolozane-tazobactam pharmaceutical compositions, treatment methods for subjects with impaired renal function, Synthesis of cephalosporin compounds, Tazobactam arginine compositions, and solid forms of ceftolozane. The last patent is expected to expire on 14th August 2035. Below are the details of the patent: